A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686
Recruiting
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/05/2025
Locations: UAB Hospital, School of Medicine/Lung Health Center, Birmingham, Alabama +101 locations
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
NCT04903080
Recruiting
This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (recurrent) or has not responded well to treatment (progressive) in children. The HER2 CAR T cells used in this trial are made from the patient's own blood. A new gene, called the H... Read More
Gender:
ALL
Ages:
Between 1 year and 22 years
Trial Updated:
08/05/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +12 locations
Conditions: Ependymoma
Register for Updates
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
NCT01876771
Recruiting
Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium-177 (Lu-DOTA-TATE) has been shown to be a safe and effective palliative therapy, and has been widely used by research groups in Europe. A brand of Lu-DOTA-TATE (Lutathera(R)) is approved for the treatment of gastroenteropancreatic NETs in Europe, the U.S., and more recently in Canada. While Lutathera(R) is... Read More
Gender:
ALL
Ages:
Between 14 years and 90 years
Trial Updated:
08/05/2025
Locations: Cross Cancer Institute, Edmonton, Alberta
Conditions: Carcinoma, Neuroendocrine
Register for Updates
Short Duration Electrical Stimulation to Improve Outcomes After Cubital Tunnel Release (SELECT) Trial
NCT05980767
Recruiting
A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/05/2025
Locations: Hamilton General Hospital, Hamilton, Ontario +1 locations
Conditions: Neuropathy;Peripheral
Register for Updates
TIDHI Mental Health in IBD Patients Study
NCT07013578
Recruiting
The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. Both groups will be receiving the same type of therapy, Healing Circuits™, but the group receiving the therapy via the onl... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/05/2025
Locations: Toronto Immune and Digestive Health Institute, North York, Ontario
Conditions: Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD)
Register for Updates
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805
Recruiting
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/05/2025
Locations: WISPer site in Phoenix, AZ, Phoenix, Arizona +7 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Testing an Alliance-Focused Dialectical Behaviour Therapy Training for Borderline Personality Disorder
NCT07119541
Recruiting
The study evaluates the feasibility, acceptability, and effect sizes of two alliance-focused dialectical behavior therapy (DBT) training interventions to improve therapists' abilities to recognize and respond to alliance ruptures with clients with borderline personality disorder (BPD). Participants will be randomly assigned to receive either a 4-week training as usual (TAU), which include didactic training plus reflective practice (i.e., thinking about past actions to gain insight for future act... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: York University, Toronto, Ontario
Conditions: Borderline Personality Disorder, Emotion Dysregulation
Register for Updates
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
NCT04289142
Recruiting
Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investiga... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/05/2025
Locations: Royal Columbian Hospital, Vancouver, British Columbia +5 locations
Conditions: Delirium, Cognitive Dysfunction, Cognition Disorder, Neurocognitive Disorders, Mental Disorders, Confusion, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Signs and Symptoms, Dexmedetomidine, Hypnotics and Sedatives, Central Nervous System Depressants, Physiological Effects of Drugs, Analgesics, Non-Narcotic, Analgesics, Molecular Mechanisms of Pharmacological Action
Register for Updates
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
NCT05538130
Recruiting
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times p... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/05/2025
Locations: Highlands Oncology Group, Fayetteville, Arkansas +47 locations
Conditions: Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer
Register for Updates
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
NCT06356883
Recruiting
The standard of care for glioblastoma (GBM) treatment involves maximal resection followed by concomitant radiotherapy and temozolomide. Progression-free survival (PFS) with this treatment is only 6.9 months and relapse is inevitable. At relapse, there is no consensus regarding the optimal therapeutic strategy. The rationale behind the fact that limited chemotherapy agents are available in the treatment of malignant gliomas is related to the blood-brain barrier (BBB), which impedes drug entry to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: CHUS, Sherbrooke, Quebec
Conditions: Glioblastoma Multiforme, Relapse
Register for Updates
Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression
NCT07094789
Recruiting
The goal of this clinical trial is to evaluate the safety and initial effectiveness of Magnetic Resonance-guided focused ultrasound neuromodulation using the Next Generation Dome Helmet (NGDH) device in patients with treatment-resistant depression. This is a prospective, single-arm, non-randomized study. Participants will: * Undergo two focused ultrasound treatment sessions targeting nodes of the cortical-striatal-thalamic circuit (CSTC) , spaced four weeks apart. * Return for follow-up visits... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2025
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Treatment-Resistant Depression, Treatment-resistant Depression (TRD)
Register for Updates
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509
Recruiting
This study is open to adults who participated in a previous clinical study with brigimadlin. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants are grouped in cohorts depending on their treatment in the previous study: * Cohort 1a got brigimadlin and continues treatment with brigimadlin * Cohort 1b got brigimadlin for 4 or less tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Precision NextGen Oncology, Beverly Hills, California +51 locations
Conditions: Solid Tumours
Register for Updates